Clinical trials: Patients With Cancer
Non Small Cell Lung Cancer
Efficacy of Re-challenge With Immune-Checkpoints Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients: a Retrospective Observational Study
This is a multicentre, retrospective, national observational study aiming to describe clinical outcomes of advanced NSCLC patients that performed an ICP re-challenge during their history of disease.
- Trial name
- RE-CHALLENGE (NCT04069663)
- Testing
- No interventional study
- Where
- France
- Volunteers
- 144 people
- Sponsor
- University Hospital, Grenoble
NSCLC Stage IIIB, Concomitant Radiochemotherapy
Chemoradiotherapy of NSCLC Stage IIIB
To evaluate the best timing of the concomitant chemoradiotherapy among patients with NSCLC stage III not resectable treated by concomitant chemo-radiotherapy, either preceded by a induction chemotherapy, or followed by a…
- Trial name
- NCT00198432
- Testing
- Paclitaxel, vinorelbine, cisplatin
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Advanced/Metastatic Colorectal Cancer
Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC
This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in combination with regorafenib in patients with mCRC.
- Trial name
- NCT06322563
- Testing
- LTC004+regorafenib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer, NSCLC
Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)
This registry is intended to measure the effect of myPlan Lung Cancer™ test has on influencing treatment decisions of Oncologists when added to standard clinical-pathological parameters in patients with early stage NSCLC.
- Conditions
- Lung Cancer, NSCLC, NSCLC Adenocarcinoma
- Trial name
- ONC006 (NCT02121899)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Activating mutations in the fms like tyrosine kinase 3 (FLT3) gene are observed in approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML).
- Trial name
- HOVON 156 AML (NCT04027309)
- Testing
- Gilteritinib, Midostaurin
- Where
- 193 sites in Australia, Austria and 11 more
- Volunteers
- 777 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
Lung Cancer
Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and RNA and identify biomarkers related to cancer.
- Trial name
- NCT00907699
- Testing
- DNA analysis, RNA analysis, fluorescence in situ hybridization
- Sponsor
- Case Comprehensive Cancer Center
Hematologic Malignancy, Stem Cell Transplantation
Physiotherapy in Hematopoietic Stem Cell Transplantation
Research project with patients undergoing allogeneic hematopoietic transplantation in the hematology and hemotherapy Clinical Hospital Universitario Virgen de la Arrixaca.
- Trial name
- TRAS (NCT02193399)
- Testing
- Physiotherapy in patients with stem cell transplantation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Universidad Católica San Antonio de Murcia
Glioblastoma
Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma
The purpose of this study is to estimate the capacity of the multimodal imaging parameters measured at 15 days and 2 months of initiation of treatment with bevacizumab, to measure changes in clinical status (sensitivity to…
- Trial name
- IMAGLIO (NCT02841332)
- Testing
- F-MISO, Cerebral magnetic resonance imagery, Bevacizumab
- Where
- France
- Volunteers
- 6 people
- Sponsor
- University Hospital, Toulouse
Acute Lymphoblastic Leukemia, B-precursor, Non-Hodgkin Lymphoma, B-cell
T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
This phase 1 / 2 study will evaluate the response of B-cell malignancies expressing CD19 to autologous T cells transduced with a second generation anti-CD19 chimeric antigen receptor in children and young adults.
- Trial name
- NCT02772198
- Testing
- CD19 CAR T cells
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Sheba Medical Center
Multiple Myeloma
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
The aim of this phase I/II trial is to determine the maximal tolerated dose (MTD) of carfilzomib together with pegylated liposomal doxorubicin hydrochloride (PLD) with or without dexamethasone, and then to establish the efficacy…
- Trial name
- NCT01246063
- Testing
- carfilzomib, pegylated liposomal doxorubicin (PLD), Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Central Nervous System Neoplasms, Lymphoma, Large B-Cell, Diffuse
Coproporphyrine Isomers and Methotrexate Elimination
High dose methotrexate (MTX) is responsible of severe toxicity in patients in whom elimination from plasma is delayed. Factors responsible for MTX accumulation are partly known but some patients still experience toxicity despite…
- Conditions
- Central Nervous System Neoplasms, Lymphoma, Large B-Cell, Diffuse, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma
- Trial name
- COMETH (NCT00822432)
- Where
- 2 sites in France
- Volunteers
- 85 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well selumetinib works in treating patients with biliary cancer that cannot be removed by surgery.
- Conditions
- Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer
- Trial name
- NCT00553332
- Testing
- selumetinib, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL)
Tumor Registry of Lymphatic Neoplasia
The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)
- Trial name
- TLN-Registry (NCT00889798)
- Volunteers
- 3,795 people
- Sponsor
- iOMEDICO AG
Colorectal Neoplasms, Metastases, Neoplasm
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
This is a phase II, multicenter, target enrollment of 250 evaluable patients, open-label study of cetuximab in patients with refractory, metastatic colorectal carcinoma.
- Trial name
- NCT00044863
- Testing
- Erbitux (Cetuximab)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
This study is for people with colorectal cancer, who have tumors that cannot be completely removed by surgery. This study is being done to find out how long it takes tumors to grow after patients receive the drugs capecitabine…
- Trial name
- NCT00159432
- Testing
- Oxaliplatin, Bevacizumab, Capecitabine
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Southern California
Breast Cancer
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
This clinical trial is evaluating a drug called AC699 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer.
- Trial name
- NCT05654532
- Testing
- AC699
- Where
- 9 sites in United States
- Volunteers
- 100 people
- Sponsor
- Accutar Biotechnology Inc
Small Cell Lung Cancer and Other Solid Tumors
APG-1252 in Patients With SCLC or Advanced Solid Tumors
APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w.
- Trial name
- NCT03387332
- Testing
- APG-1252
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Ascentage Pharma Group Inc.
Bladder Cancer, Urothelial Carcinoma
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
This study aims to demonstrate that home instillation of UGN-102 is a feasible alternative to instillation in a clinical setting, which might mitigate patient challenges (logistical, expense, and comfort) when receiving treatment…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- NCT05136898
- Testing
- UGN-102
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- UroGen Pharma Ltd.
Tumor
Evaluation of Questionnaires of Tumor Patients With and Without Additive Homeopathic Therapy
Tumor patients receiving conventional tumor therapies are included into this study. The patients are randomized into two groups receiving either additive homeopathic therapy or not.
- Trial name
- NCT00861432
- Testing
- additive homeopathic treatment
- Where
- Austria
- Volunteers
- 400 people
- Sponsor
- Medical University of Vienna
Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma, Patients Treated With Rituximab-CHOP or Rituximab-CVP
Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab
This study is a retrospective analysis to identify factors influencing hepatitis B virus reactivation in patients treated with rituximab containing chemotherapy.
- Trial name
- NCT01311232
- Where
- 4 sites in China, Malaysia and 2 more
- Volunteers
- 600 people
- Sponsor
- Samsung Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.